NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
30/07/2024
Voltar para busca
Dado oficial do USPTO
NEURACTHEL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
NEURACTHEL
ST13
US500000079348994Classe
3, 5, 10
Pedido
79348994
Registro
7265343
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
30/07/2024
Tipo de marca
Verbal
Classes Nice
3, 5, 10
Data de depósito
07/04/2022
Data de registro
09/01/2024
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/01/2024
Última transação
09/01/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
IE
Examinador
KING, LINDA
Localização atual
Historical data usage
Titulares e representantes
Titulares
Clinuvel Europe Ltd
Representantes
Mark M. Friedman Dr. Mark Friedman Ltd.
Classificação técnica
Classes Nice
Classe 3Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 3
Non-medicated cosmetics; cosmetics for protecting against light and UV; cosmeticscosmetic products as leave-onlotionscreamsointments and other formulations as well as cosmetic products for topical use; non-medicated *skin care* preparations for protecting the skin against light and UV; non-medicated skin *care* photoprotection preparations; *non-medicated* sun care preparations for cosmetic use; sun-tanning preparations; *cosmetic* suntan lotions; suntan oils *for cosmetic purposes;* tanning gels; cosmetic preparations for skin care containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetics for tanning the skin containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetic preparations for tanning the skin without sunlight containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; sun screen preparations; cosmetic preparations for protecting the skin from the sun's rays; cosmetics for protecting the skin from sunburn; sun protecting creams; sun *block preparations;* sun block; sun blocking preparations; sun-block lotions; sun blocking oils; SPF sun block sprays; *lip balm with sun block;* sun blocking lipsticks; *cosmetic sunscreen preparations;* waterproof sunscreen *preparations;* water-resistant sunscreen *preparations;* sunscreen preparations; sunscreen creams; sunscreen lotions; sunscreen sticks; cosmetic foams containing sunscreen *preparations; sunscreen* preparations for protecting the hair from the sun; *nonmedicated cosmetic preparations against sunburns;* non-medicated *sun care preparations* for skin care after exposure to the sun's rays.
Classe 5
Pharmaceuticals *for the prevention and treatment of neurologicalendocrinologicaldegenerative disorders;* pharmaceutical drugs *for the prevention and treatment of epidermal problemsdamaged skin and tissue;* pharmaceutical products for endocrineneuroendocrinesystemicinflammatoryacute disorders such as sepsisshockhaemorrhagic shockacute bleeding disorderschronic disorders requiring preventioncurative or palliative treatment where no other treatments are effective or safe; pharmaceutical preparations *for the prevention and treatment of viralmetabolicgeneticendocrinemusculoskeletalophthalmiccardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricimmune system related diseases and disorders;* pharmaceuticals used for cerebrovascular accidents *in the nature of strokes*; pharmaceutical preparations for the prevention and treatment of arterial ischemic strokes; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the prevention and treatment of cardiovascular and cerebrovascular diseases; cardiovascular drugs for use in treating hypertension; cardiovascular preparations *for the prevention and treatment of cardiometabolic conditions;* cardiovascular pharmaceuticals *for the prevention and treatment of ischemic syndromes;* cardiovascular pharmaceutical preparations *for the prevention and treatment of cardiomyopathies;* cardiovascular agents for medical purposes; cardiovascular drugs used in treating *cardiogenic shocks;* cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; cardiovascular drugs used in treating congestive heart failure (CHF); pharmaceutical preparations containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; medicated sun care preparationssun tanning preparations for pharmaceutical purposes containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; *dermatologicalsdermatological preparationsdermatological pharmaceutical substancesdermatological pharmaceutical products;* medicinal creams for the protection of the skin; skin care creams for medical use; skin care preparations for medical use; medicated skin creams and lotions; medicated *skin care* creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; *medicated chemical and biological skin care preparations and chemical reagents* for medical purposes which contain analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; *drug afamelanotide in aqueous and gel formulations;* pharmaceutical implants *comprising living tissue;* subcutaneous implants containing *living tissue and also containing* afamelanotide; implantable *subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the prevention and treatment of neurologicalendocrinologicaldegenerative disorders; implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations and containing afamelanotide for the prevention and treatment of skin related diseases and disorder*
Classe 10
Medical apparatusdevices and instruments *for accessing subcutaneous structures of the human body for the purpose of administering medical treatment;* apparatus for drug administration*namelydrug delivery catheters;* devices for use in the administration of pharmaceuticalsimplantable drug delivery ports; controlled rate release apparatus for dispensing pharmaceutical substances*namelyimplantable drug delivery pumps;* medical fluid injectors; injection syringes; medical syringes; implantable subcutaneous drug delivery *ports and pumps*
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/07/2024
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
25/06/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
25/06/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/06/2024
FIMP
FINAL DISPOSITION PROCESSED
24/06/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/04/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/01/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
09/01/2024
GPNX
NOTIFICATION PROCESSED BY IB
24/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/10/2023
PUBO
PUBLISHED FOR OPPOSITION
24/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/10/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/10/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/09/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/09/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/09/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/09/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/09/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/09/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/09/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
14/09/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
14/09/2023
RFNT
REFUSAL PROCESSED BY IB
20/04/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/03/2023
RFRR
REFUSAL PROCESSED BY MPU
28/03/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/02/2023
CNRT
NON-FINAL ACTION WRITTEN
01/02/2023
DOCK
ASSIGNED TO EXAMINER
25/01/2023
MAFR
APPLICATION FILING RECEIPT MAILED
13/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NEURACTHEL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.